A randomized, double-blind, placebo-controlled study involved 81 volunteers aged 45–65 years, particularly susceptible to aging effects due to stressful jobs.
Over a 12-week period, participants taking 100 mg of EPIGEN12™ demonstrated:
Improved Leukocyte Telomere Length (LTL): A crucial indicator of cellular aging.
Enhanced Quality of Life (QOL): Including significant improvements in physical activity and sleep indices compared to placebo.
Prevention of Epigenetic Aging: Slowing biological aging, in contrast to the placebo group, which experienced an increase.
All participants tolerated the supplement well, with no adverse effects reported.